Image-Guided Hypofractionated Radiation Therapy with Stereotactic Radiosurgery Boost and Combination Chemotherapy in Treating Patients with Stage II-III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery
This phase I clinical trial studies the best dose of image-guided hypofractionated radiation therapy (RT) when given together with stereotactic RT boost and combination chemotherapy in treating patients with stage II-III non-small cell lung cancer (NSCLC) that cannot be removed by surgery. Hypofractionated RT delivers higher doses of RT over a shorter period of time and may kill more tumor cells and have fewer side effects. Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving RT together with combination chemotherapy may kill more tumor cells and allow doctors to save the part of the body where the tumor started.